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ORIGINAL INVESTIGATION
Cardiovascular risk reduction 
with once-weekly semaglutide in subjects 
with type 2 diabetes: a post hoc analysis 
of gender, age, and baseline CV risk profile 
in the SUSTAIN 6 trial
Lawrence A. Leiter1*, Stephen C. Bain2, Irene Hramiak3, Esteban Jódar4, Sten Madsbad5, Theis Gondolf6, 
Thomas Hansen6, Ingrid Holst6 and Ildiko Lingvay7
Abstract 
Background: The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0 mg) significantly reduced 
major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high CV risk. 
The effects of gender, age and baseline CV risk on outcomes are important considerations for further study.
Methods: Subjects were grouped according to gender, age (50–65 years and > 65 years), and CV risk profile at 
baseline (prior myocardial infarction [MI] or stroke vs no prior MI or stroke, and established CV disease [CVD] vs CV risk 
factors alone, including subjects with chronic kidney disease). Time to MACE and its individual components (CV death, 
nonfatal MI, nonfatal stroke), hospitalization for unstable angina or heart failure, and revascularization (coronary and 
peripheral) were analyzed for all subgroups. Additional analyses were performed for gender and age to investigate 
change from baseline in  HbA1c and body weight, as well as tolerability.
Results: A total of 3297 subjects were included. The majority of subjects (60.7%) were male; 43% were > 65 years 
of age; 41.5% had a history of MI or stroke; and 76.8% had established CVD. Compared with placebo, semaglutide 
reduced the risk of the first occurrence of MACE and each MACE component consistently across all subgroups 
(gender, age, and baseline CV risk profile). Revascularizations,  HbA1c and body weight were also reduced consistently 
across all subgroups compared with placebo. Gastrointestinal adverse events in all treatment groups were more com-
mon among women than men, but rates of premature treatment discontinuation were similar for both genders.
Conclusions: In this post hoc analysis of SUSTAIN 6, once-weekly semaglutide vs placebo reduced the risk of MACE 
in all subjects included in the trial, regardless of gender, age, or baseline CV risk profile.
Trial registry Clinicaltrials.gov, Identifying number: NCT01720446, Date of registration: October 29, 2012
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Background
Cardiovascular disease (CVD) is the leading cause of 
morbidity and mortality in people with type 2 diabe-
tes (T2D) [1, 2], and diabetes itself confers a substantial 
independent risk of coronary heart disease, stroke, and 
death from other vascular causes [3]. Current diabetes 
guidelines recommend multifactorial CV risk manage-
ment and the preferential use of a glucagon-like pep-
tide-1 receptor agonist  (GLP-1RA) or sodium–glucose 
cotransporter-2 inhibitor with proven CV benefits as a 
first choice add-on to metformin in patients with T2D 
and established atherosclerotic CVD [2, 4]. Semaglutide 
is a GLP-1 analogue approved as a once-weekly, subcu-
taneous treatment for T2D [5, 6]. The phase 3 SUSTAIN 
(Semaglutide Unabated Sustainability in Treatment of 
Type 2 Diabetes) clinical trial program evaluated the effi-
cacy and safety of semaglutide in subjects with T2D in a 
range of patient populations across the continuum of dia-
betes care [7–14]. In the SUSTAIN 6 CV outcomes trial 
(CVOT), once-weekly semaglutide (0.5 or 1.0 mg) added 
to standard of care significantly reduced the occurrence 
of a first major adverse CV event (MACE: CV death, 
nonfatal myocardial infarction [MI], or nonfatal stroke) 
vs placebo over 2  years in 3297 subjects with T2D and 
high CV risk [12]. Given the increasing emphasis on indi-
vidualized patient care in the management of T2D [4], 
this post hoc analysis assessed the effects of gender, age, 
and baseline CV risk on the reduction of CV risk in the 
SUSTAIN 6 trial.
Methods
SUSTAIN 6 study design
The design of SUSTAIN 6 (clinicaltrials.gov 
NCT01720446) has been described previously [12]. In 
brief, SUSTAIN 6 was a randomized, double-blind, pla-
cebo-controlled, parallel-group trial to evaluate once-
weekly semaglutide 0.5 or 1.0  mg vs volume-matched 
placebo over a 104-week treatment period plus a 5-week 
follow-up period. The trial was conducted in compliance 
with the International Conference on Harmonisation 
Good Clinical Practice guidelines and the Declaration of 
Helsinki [15, 16]. The protocol was approved by local eth-
ics committees and institutional review boards. Written 
informed consent was obtained from all subjects before 
trial commencement.
A total of 3297 subjects with T2D  (HbA1c ≥ 7%) 
were randomized to receive once-weekly semaglutide 
0.5 or 1.0  mg or placebo for 104  weeks. Subjects were 
≥ 50 years of age with established CVD (defined as previ-
ous CV, cerebrovascular, or peripheral vascular disease), 
chronic heart failure (New York Heart Association class 
II or III), or chronic kidney disease (CKD) of stage 3 or 
higher, or were ≥ 60 years of age with at least one CV risk 
factor (microalbuminuria or proteinuria, hypertension 
and left ventricular hypertrophy, left ventricular systolic 
or diastolic dysfunction or ankle–brachial index < 0.9). 
All subjects treated with semaglutide followed a fixed 
dose-escalation regimen, with a starting dose of 0.25 mg 
for 4 weeks that escalated to 0.5 mg for 4 weeks until the 
maintenance dose (0.5 or 1.0 mg) was reached.
The primary composite outcome (MACE) was the first 
occurrence of death from CV causes, nonfatal MI, or 
nonfatal stroke. Other outcomes included time to first 
hospitalization for unstable angina and heart failure, time 
to first revascularization (coronary or peripheral), and 
changes in  HbA1c and weight. All outcomes were col-
lected after 104 weeks of treatment.
Statistical analysis
This post hoc analysis examined the effect of gender, age 
(subjects aged 50–65 and > 65 years), and CV risk profile 
at baseline on time to first occurrence of MACE, the indi-
vidual components of MACE (CV death, nonfatal MI, or 
nonfatal stroke), hospitalization for unstable angina or 
heart failure, and revascularization. Additional analyses 
were performed by gender and age to investigate changes 
from baseline in  HbA1c and body weight, adverse events 
(AEs), and hypoglycemia, as defined by the American 
Diabetes Association (ADA) [17].
For comparison of outcomes between men and women, 
estimated hazard ratios (HRs) and associated confidence 
intervals (CIs) were determined by a Cox proportional 
hazards model with an interaction between treatment 
(semaglutide, placebo) and gender as a fixed factor. Effi-
cacy and safety were assessed by age group using post 
hoc subgroup analyses of subjects ≤ 65 and > 65  years. 
Post-baseline responses for time to first occurrence of 
MACE, CV death, nonfatal MI, nonfatal stroke, hospi-
talization for unstable angina or heart failure, revascu-
larization, and change from baseline in  HbA1c and body 
weight were analyzed using a mixed model for repeated 
measurements with interaction between subgroup, ran-
domized treatment, and baseline value as covariate. No 
adjustment for multiplicity was performed. A significance 
level for interaction of 5% was considered significant. To 
investigate more general linear and non-linear effects of 
age at baseline, individual outcomes and AEs were mod-
elled as a function of age, controlling for randomized 
treatment and CVD at baseline via negative-binomial 
log regression (see “Post hoc analysis by age”). Analyses 
were based on pooled data using semaglutide 0.5 mg and 
1.0 mg doses for MACE and its components, hospitaliza-
tion due to angina or heart failure, revascularization, and 
AEs.  HbA1c and body weight were reported separately for 
both semaglutide doses following the statistical methods 
used in the primary SUSTAIN 6 trial [12].
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CV risk profile subgroups
To assess the effect of baseline CV risk profiles on 
outcomes, two separate subgroup analyses were per-
formed: (1) for subjects who had experienced a prior 
MI or stroke compared with those who had not, and (2) 
for those with established CVD, defined as prior stroke, 
ischemic heart disease (including MI), peripheral 
arterial disease, ≥ 50% arterial stenosis in any artery, 
coronary revascularization (percutaneous coronary 
intervention or coronary artery bypass graft), or heart 
failure vs those with CV risk factors alone and no mani-
festations of CVD as defined above. The risk classifica-
tion in the latter subgroup comparison differs from the 
prespecified group of evidence of CVD in SUSTAIN 
6, in which subjects with CKD stage 3 or higher were 
included [12]. In this post hoc analysis, however, sub-
jects with CKD were included in the CV risk factor 
alone group to reflect the usual definition of established 
CVD used in clinical practice. Statistical analyses were 
carried out using Cox proportional hazards models for 
time to first MACE with treatment, and treatment by 
subgroup interaction, if applicable, as fixed factor(s). 
No adjustment for multiplicity was performed. A sig-
nificance level for interaction of 5% was considered 
significant.
Results
Post hoc analysis by gender
Among 3297 subjects in the SUSTAIN 6 study 
population, 2002 were male and 1295 were female 
(Table 1A). There were no clear differences in subject 
demographics or key baseline characteristics between 
men and women, with the exception of weight (men 
tended to be heavier) and smoking status (51.7 vs 
26.1% and 56.1 vs 23.0% of men vs women had a 
history of smoking in the semaglutide and placebo 
groups, respectively). Similar proportions of male 
and female subjects completed the trial and treat-
ment. MACE occurred in lower proportions of sub-
jects treated with semaglutide vs placebo in both men 
and women, and this overall benefit was independ-
ent of gender (p = 0.45 for interaction) (Fig.  1). The 
same pattern was noted across the individual MACE 
components of CV death, nonfatal MI and nonfatal 
stroke; lower or similar proportions of both men and 
women experienced events with semaglutide vs pla-
cebo, and p-values for interaction were nonsignificant 
(p = 0.46, p = 0.34 and p = 0.74, respectively, for each 
endpoint) (Fig. 1). Gender had no apparent effect on 
first hospitalization for unstable angina (p = 0.35 for 
interaction) or heart failure (p = 0.55 for interaction), 
or time to first revascularization procedure (p = 0.50 
for interaction; Fig. 2).
Post hoc analysis by age
In the SUSTAIN 6 study, 1879 subjects were 
50–65 years of age and 1418 were > 65 years (Table 1B). 
There were no clear differences in subject demograph-
ics or key baseline characteristics between groups. 
Duration of diabetes was greater in subjects > 65 years 
compared with those ≤ 65  years (16.4 vs 12.6  years 
for the semaglutide group and 15.2 vs 12.4  years for 
the placebo group). Similar proportions of subjects 
in each age group completed the trial and treatment. 
HRs for time to first confirmed MACE were all below 
1.0 for subjects treated with semaglutide vs placebo, 
irrespective of age (p = 0.92 for interaction, Fig.  1). 
Results were consistent for the individual components 
of MACE across age groups (Fig.  1; p = 0.35, p = 0.42, 
and p = 0.45 for interaction, respectively, for CV death, 
nonfatal MI, and nonfatal stroke). Age had no appar-
ent effect on first hospitalization due to unstable angina 
(p = 0.16 for interaction), heart failure (p = 0.26 for 
interaction) or revascularization procedures (p = 0.97 
for interaction; Fig.  2). A series of regression analyses 
were conducted to assess more general linear and non-
linear trends for the incidence of MACE by age; since 
no significant effects were found, these have not been 
reported further (see Additional file 1).
Post hoc analysis by CV risk
Pooled key baseline characteristics, CV risk factors, and 
manifestation of CVD at baseline for the two CV sub-
groups [subjects with prior MI or stroke vs no prior MI 
or stroke and subjects with established CVD vs risk fac-
tors only (including CKD)] are shown in Table  1C. In 
total, 1367 subjects had a history of MI or stroke (vs 1930 
without prior history) and 2533 had established CVD (vs 
764 with CV risk factors only).
Hazard ratios for time to first confirmed MACE were 
all below 1.0 in subjects treated with semaglutide vs 
placebo, irrespective of baseline CV risk profile (Fig. 3). 
Similar results were observed across the individual com-
ponents of MACE, with the exception of CV death in 
subjects with a prior MI or stroke or with established 
CVD (p = 0.22 for interaction between subjects with 
prior MI or stroke vs no prior MI or stroke; p = 0.52 for 
interaction between subjects with established CVD vs 
risk factors only) (Fig. 2).
In the SUSTAIN 6 trial, there was no difference in 
hospitalization for angina or heart failure between 
semaglutide and placebo [12], and this result was 
independent of baseline CV risk profile (Fig.  2). The 
between-group interaction for unstable angina in sub-
jects with prior MI or stroke compared with no prior MI 
or stroke was significant (p = 0.02 for interaction), with 
Page 4 of 12Leiter et al. Cardiovasc Diabetol           (2019) 18:73 
Table 1 Baseline characteristics and demographics of subjects in the SUSTAIN 6 trial
A. Post hoc analysis by gender
Semaglutide Placebo
Male Female Male Female
 Subject demographics
  Full analysis set, N 1013 635 989 660
  Trial completers, n (%) 959 (94.7) 602 (94.8) 926 (93.6) 623 (94.4)
  Treatment completers, n (%) 773 (76.3) 481 (75.7) 788 (79.7) 514 (77.9)
 Baseline  characteristicsa
  Age, years 64.6 (7.3) 64.8 (7.1) 64.6 (7.6) 64.6 (7.5)
  Body weight, kg 96.7 (20.5) 85.4 (19.0) 95.8 (21.0) 86.0 (18.4)
  BMI, kg/m2 32.3 (5.9) 33.7 (6.6) 32.1 (6.0) 33.9 (6.3)
  Diabetes duration, years 13.9 (8.1) 14.5 (8.4) 13.5 (8.0) 13.8 (8.1)
  HbA1c, % 8.6 (1.4) 8.8 (1.6) 8.6 (1.4) 8.8 (1.6)
  Smoking status (never/previous/current), 
%
33.5/51.7/14.8 65.4/26.1/8.5 30.1/56.1/13.7 66.8/23.0/10.2
B. Post hoc analysis by age
Semaglutide Placebo
≤ 65 years > 65 years ≤ 65 years > 65 years
 Subject demographics
  Full analysis set, N 950 698 929 720
  Trial completers, n (%) 899 (94.6) 662 (94.8) 875 (94.2) 674 (93.6)
  Treatment completers, n (%) 745 (78.4) 509 (72.9) 745 (80.2) 557 (77.4)
 Baseline  characteristicsb
  Age, years 59.7 (4.1) 71.4 (4.7) 59.2 (4.3) 71.6 (4.5)
  Females, % 38.4 38.7 40.9 38.9
  Body weight, kg 94.0 (21.1) 90.0 (19.8) 93.0 (21.4) 90.5 (19.3)
  BMI, kg/m2 33.3 (6.4) 32.2 (5.9) 33.1 (6.4) 32.4 (5.8)
  Diabetes duration, years 12.6 (7.2) 16.4 (8.9) 12.4 (7.4) 15.2 (8.5)
  HbA1c, % 8.9 (1.6) 8.4 (1.2) 8.9 (1.6) 8.4 (1.3)
  Smoking status (never/previous/cur-
rent),  %
47.0/37.1/16.0 44.1/48.4/7.5 45.3/39.0/15.7 44.2/47.9/7.8
C. Post hoc analyses by CV risk profile at baseline
Semaglutide Placebo Semaglutide Placebo
Prior MI/
stroke
No prior MI/
stroke
Prior MI/
stroke
No prior MI/
stroke
Established 
CVD
CV risk 
factors
Established 
CVD
CV risk factors
 Full analysis 
set, N
673 975 694 955 1262 386 1271 378
 Baseline characteristics
  Age, years 63.8 (7.5) 65.2 (6.9) 63.6 (7.9) 65.3 (7.2) 64.2 (7.3) 66.1 (6.5) 64.2 (7.7) 66.0 (6.7)
  Female, n (%) 208 (30.9) 427 (43.8) 225 (32.4) 435 (45.5) 445 (35.3) 190 (49.2) 463 (36.4) 197 (52.1)
  Diabetes  
duration, years
13.7 (8.5) 14.5 (8.0) 13.3 (8.1) 13.8 (8.0) 14.0 (8.4) 14.8 (7.6) 13.3 (7.9) 14.6 (8.2)
  BMI, kg/m2 32.6 (6.0) 33.0 (6.4) 32.7 (6.2) 32.8 (6.2) 32.8 (6.1) 32.8 (6.5) 33.0 (6.2) 32.3 (6.1)
  HbA1c, % 8.8 (1.6) 8.7 (1.4) 8.7 (1.5) 8.7 (1.4) 8.7 (1.5) 8.7 (1.4) 8.7 (1.5) 8.7 (1.5)
 CV risk factors
  Systolic blood 
pressure, 
mmHg
134.6 (17.7) 136.9 (17.3) 134.9 (17.1) 135.5 (16.6) 135.5 (17.5) 137.5 (17.5) 134.9 (16.6) 136.5 (17.4)
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a significant reduction in hospitalization for unstable 
angina for semaglutide vs placebo in subjects with no 
prior MI or stroke (p = 0.03). No significant interactions 
were noted for hospitalization for heart failure between 
the various risk groups (Fig.  2; p = 0.59 for interaction 
between subjects with prior MI or stroke vs no prior MI 
or stroke and p = 0.93 for interaction between subjects 
with established CVD vs CV risk factors only).
Semaglutide reduced time to first revasculariza-
tion vs placebo in the overall study; this result was 
observed regardless of baseline CV risk profile, with 
no significant differences between subgroups (p = 0.25 
for interaction between subjects with prior MI or 
stroke vs no prior MI or stroke and p = 0.27 for inter-
action between subjects with established CVD vs CV 
risk factors only).
Table 1 (continued)
C. Post hoc analyses by CV risk profile at baseline
Semaglutide Placebo Semaglutide Placebo
Prior MI/
stroke
No prior MI/
stroke
Prior MI/
stroke
No prior MI/
stroke
Established 
CVD
CV risk 
factors
Established 
CVD
CV risk factors
  Diastolic blood 
pressure, 
mmHg
76.8 (9.9) 77.1 (10.1) 76.7 (10.4) 77.4 (9.8) 76.7 (10.0) 77.9 (9.8) 77.0 (10.2) 77.5 (9.6)
  Total  
cholesterol, 
mmol/L 
[mean (CoV)]
4.2 (26.8) 4.4 (25.5) 4.2 (27.9) 4.3 (26.5) 4.3 (26.9) 4.4 (23.6) 4.2 (27.6) 4.4 (25.4)
  eGFR, mL/
min/1.73 m2 
[mean (CoV)]
72.1 (39.2) 70.1 (41.4) 73.8 (39.8) 69.0 (44.6) 72.9 (38.7) 64.9 (44.8) 73.9 (39.7) 61.7 (49.2)
  Current 
smoker,  
n (%)
106 (15.8) 98 (10.1) 109 (15.7) 93 (9.74) 170 (13.5) 34 (8.8) 167 (13.1) 35 (9.3)
 Manifestation of CVD
  Prior MI, n (%) 530 (78.8) – 542 (78.1) – 530 (42.0) – 542 (42.6) –
  Ischemic heart 
disease,  
n (%)
571 (84.8) 417 (42.8) 589 (84.9) 417 (43.7) 988 (78.3) – 1006 (79.2) –
  Prior stroke, 
n (%)
191 (28.4) – 210 (30.3) – 191 (15.1) – 210 (16.5) –
  Peripheral 
arterial  
disease, n (%)
87 (12.9) 139 (14.3) 89 (12.8) 138 (14.5) 226 (17.9) – 227 (17.9) –
  ≥ 50% arterial 
stenosis,  
n (%)
327 (48.6) 240 (24.6) 361 (52.0) 239 (25.0) 567 (44.9) – 600 (47.2) –
  Percutaneous 
coronary 
intervention, 
n (%)
327 (48.6) 163 (16.7) 342 (49.3) 180 (18.8) 490 (38.8) – 522 (41.1) –
  Coronary 
artery 
bypass graft, 
n (%)
182 (27.0) 106 (10.9) 182 (26.2) 107 (11.2) 288 (22.8) – 289 (227) –
  Heart failure, 
n (%)
187 (27.8) 194 (19.9) 185 (26.7) 211 (22.1) 381 (30.2) – 396 (31.2) –
Data presented as mean (SD) unless otherwise indicated. Data were pooled for semaglutide groups and placebo groups in each SUSTAIN 6 subgroup
BMI body mass index, CoV coefficient of variation, CV cardiovascular, CVD cardiovascular disease, eGFR estimated glomerular filtration rate, MI myocardial infarction, 
SD standard deviation
a Numbers are based on an in-trial analysis comprising events with onset on or after the day of randomization and until end of trial
b Data were pooled for semaglutide groups and placebo groups in each SUSTAIN 6 subgroup
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Event/subgroup
Events (subjects)
semaglutide / placebo HR [95% CI]
Interaction
p-value
MACE
All subjects 108 (1648) / 146 (1649) 0.74 [0.58;0.95]
Gender
Male 73 (1013) / 103 (989) 0.68 [0.50;0.92]
0.45
Female 35 (635) / 43 (660) 0.84 [0.54;1.31]
Age, years
≤65 57 (950) / 76 (929) 0.72 [0.51;1.02]
0.92
>65 51 (698) / 70 (720) 0.74 [0.52;1.06]
CV risk
Prior MI/stroke 66 (673) / 88 (694) 0.76 [0.55;1.05]
0.75
No prior MI/stroke 42 (975) / 58 (955) 0.70 [0.47;1.04]
Established CVD 97 (1262) / 124 (1271) 0.78 [0.60;1.01]
0.22
CV risk factors 11 (386) / 22 (378) 0.48 [0.23;0.99]
CV death
All subjects 44 (1648) / 46 (1649) 0.98 [0.65;1.48]
Gender
Male 30 (1013) / 34 (989) 0.86 [0.53;1.40]
0.46
Female 14 (635) / 12 (660) 1.21 [0.56;2.61]
Age, years
≤65 26 (950) / 22 (929) 1.15 [0.65;2.03]
0.35
>65 18 (698) / 24 (720) 0.77 [0.42;1.43]
CV risk
Prior MI/stroke 27 (673) / 23 (694) 1.22 [0.70;2.11]
0.22
No prior MI/stroke 17 (975) / 23 (955) 0.72 [0.38;1.35]
Established CVD 40 (1262) / 40 (1271) 1.01 [0.65;1.56]
0.52
CV risk factors 4 (386) / 6 (378) 0.65 [0.18;2.30]
Nonfatal MI
All subjects 47 (1648) / 64 (1649) 0.74 [0.51;1.08]
Gender
Male 32 (1013) / 48 (989) 0.64 [0.41;1.01]
0.34
Female 15 (635) / 16 (660) 0.97 [0.48;1.96]
Age, years
≤65 22 (950) / 34 (929) 0.63 [0.37;1.07]
0.42
>65 25 (698) / 30 (720) 0.85 [0.50;1.45]
CV risk
Prior MI/stroke 30 (673) / 44 (694) 0.70 [0.44;1.11]
0.67
No prior MI/stroke 17 (975) / 20 (955) 0.83 [0.43;1.58]
Established CVD 44 (1262) / 54 (1271) 0.82 [0.55;1.22]
0.13
CV risk factors 3 (386) / 10 (378) 0.29 [0.08;1.05]
Nonfatal stroke
All subjects 27 (1648) / 44 (1649) 0.61 [0.38;0.99]
Gender
Male 18 (1013) / 27 (989) 0.65 [0.36;1.17]
0.74
Female 9 (635) / 17 (660) 0.55 [0.24;1.22]
Age, years
≤65 12 (950) / 23 (929) 0.51 [0.25;1.02]
0.45
>65 15 (698) / 21 (720) 0.73 [0.38;1.42]
CV risk
Prior MI/stroke 16 (673) / 25 (694) 0.66 [0.35;1.23]
0.75
No prior MI/stroke 11 (975) / 19 (955) 0.56 [0.27;1.18]
Established CVD 23 (1262) / 37 (1271) 0.62 [0.37;1.04]
0.87
CV risk factors 4 (386) / 7 (378) 0.55 [0.16;1.89]
Favors semaglutide
HR (semaglutide:placebo)
0 0.5 1 1.5 2 2.5 3
Favors placebo
Fig. 1 Treatment differences in MACE and MACE components in SUSTAIN 6. Analysis of time from randomization to first event adjudication 
committee-confirmed event. Subjects were censored at their planned end-of-trial visit, last direct subject-site contact or all-cause death of the 
subject, whichever occurred first. Estimated HRs and associated CIs are from a Cox proportional hazards model with an interaction between 
treatment (semaglutide, placebo) and subgroups as fixed factors. The p-values are 2-sided for test for heterogeneity of treatment between 
subgroups. CI confidence interval, CV cardiovascular, CVD cardiovascular disease, HR hazard ratio, MI myocardial infarction
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Reductions in  HbA1c and body weight by gender and age
Significantly greater reductions in  HbA1c were achieved 
by subjects treated with semaglutide than by those 
receiving placebo, and this decrease was consistent for 
both genders (ETD for semaglutide 0.5 and 1.0  mg vs 
placebo: − 0.65% [95% CI − 0.80; − 0.49] and − 0.96% 
[95% CI − 1.11; − 0.81], respectively in males and 
− 0.75% [95% CI − 0.94; − 0.56] and − 1.09% [95% 
CI − 1.28; − 0.89], respectively in females; Fig.  4a) 
and across age groups (ETDs for semaglutide 0.5 and 
1.0 mg vs placebo were − 0.72% [95% CI − 0.88; − 0.56] 
and − 1.13% [95% CI − 1.29; − 0.97], respectively, 
Event/subgroup
Events (subjects)
semaglutide / placebo HR [95% CI]
Interaction
p-value
Hospitalization for
unstable angina
All subjects 22 (1648) / 27 (1649) 0.82 [0.47;1.44]
Gender
Male 13 (1013) / 19 (989) 0.66 [0.33;1.35]
0.35
Female 9 (635) / 8 (660) 1.17 [0.45;3.03]
Age, years
≤65 16 (950) / 14 (929) 1.40 [0.80;2.44]
0.16
>65 6 (698) / 13 (720) 0.47 [0.18;1.24] 
CV risk
Prior MI/stroke 17 (673) / 12 (694) 1.47 [0.70;3.08] 
0.02 
No prior MI/stroke 5 (975) / 15 (955) 0.32 [0.12;0.89] 
Established CVD 22 (1262) / 25 (1271) 0.89 [0.50;1.57] 
0.99
CV risk factors 0 (386) / 2 (378) 0 [0;NE]
Hospitalization for
heart failure
All subjects 59 (1648) / 54 (1649) 1.11 [0.77;1.61]
Gender
Male 41 (1013) / 34 (989) 1.18 [0.75;1.86]
0.55
Female 18 (635) / 20 (660) 0.93 [0.49;1.76]
Age, years
≤65 30 (950) / 21 (929) 1.40 [0.80;2.44]
0.26 
>65 29 (698) / 33 (720) 0.91 [0.55;1.49] 
CV risk
Prior MI/stroke 27 (673) / 28 (694) 0.99 [0.58;1.68] 
0.59 
No prior MI/stroke 32 (975) / 26 (955) 1.21 [0.72;2.04]
Established CVD 52 (1262) / 48 (1271) 1.09 [0.74;1.62] 
0.93 
CV risk factors 7 (386) / 6 (378) 1.15 [0.39;3.41] 
Revascularization
All subjects 83 (1648) / 126 (1649) 0.65 [0.50;0.86]
Gender
Male 55 (1013) / 87 (989) 0.61 [0.43;0.85]
0.50
Female 28 (635) / 39 (660) 0.74 [0.46;1.20]
Age, years
≤65 48 (950) / 71 (929) 0.65 [0.45;0.94]
0.97
>65 35 (698) / 55 (720) 0.65 [0.42;0.99] 
CV risk
Prior MI/stroke 49 (673) / 66 (694) 0.76 [0.52;1.10] 
0.25 
No prior MI/stroke 34 (975) / 60 (955) 0.55 [0.36;0.83] 
Established CVD 80 (1262) / 117 (1271) 0.68 [0.51;0.90]
0.27 
CV risk factors 3 (386) / 9 (378) 0.32 [0.09;1.19] 
Favors semaglutide
HR (semaglutide:placebo)
0 0.5 1 1.5 2 2.5 3 3.5
Favors placebo
Fig. 2 Treatment differences in hospitalization for unstable angina or heart failure, and revascularization in SUSTAIN 6. Analysis of time from 
randomization to first event adjudication committee-confirmed event. Subjects were censored at their planned end-of-trial visit, last direct 
subject-site contact or all-cause death of the subject, whichever occurred first. Estimated HRs and associated CIs are from a Cox proportional 
hazards model with an interaction between treatment (semaglutide, placebo) and subgroups as fixed factors. The p-values are 2-sided for test for 
heterogeneity of treatment between subgroups. CI confidence interval, CV cardiovascular, HR hazard ratio, NE non-estimable
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Fig. 3 Time from baseline to first confirmed MACE in SUSTAIN 6. In subjects with a prior MI/stroke (a) vs no prior MI/stroke (b) (p = 0.75 for 
interaction) and in subjects with established CVD (c) vs CV risk factors only (including CKD) (p = 0.22 for interaction) (d). Kaplan–Meier estimates: 
Cox proportional hazards models of time from randomization to first EAC-confirmed MACE in the full analysis set, and treatment by subgroup 
interaction, if applicable, as fixed factor(s). Data were pooled for semaglutide groups and placebo groups, respectively. CI confidence interval, CKD 
chronic kidney disease, CV cardiovascular, CVD cardiovascular disease, EAC event adjudication committee, HR hazard ratio, MACE major adverse 
cardiovascular event, MI myocardial infarction
Fig. 4 Change from baseline in  HbA1c and body weight by gender (a, c) and age (b, d) in SUSTAIN 6. ETD estimated treatment difference
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in ≤ 65  years, and − 0.66% [95% CI − 0.84; − 0.47] 
and − 0.85% [95% CI − 1.03; − 0.67], respectively, in 
> 65  years; Fig.  4b). The  p-values for all comparisons 
between gender and age groups were nonsignificant.
Greater weight loss was observed with semaglutide 
0.5 and 1.0 mg compared with placebo in both genders 
(ETD − 2.86  kg [95% CI − 3.52; − 2.19] and − 3.68  kg 
[95% CI − 4.33; − 3.03] in males and − 3.04 kg [95% CI 
− 3.85; − 2.23] and − 5.27 kg [95% CI − 6.11; − 4.43] in 
females; Fig. 4c) and in subjects ≤ 65 and > 65 years of 
age (ETDs for semaglutide 0.5 and 1.0  mg vs placebo: 
− 2.90 kg [95% CI − 3.58; − 2.23] and − 3.87 kg [− 4.56; 
− 3.18], respectively, and − 3.02  kg [− 3.82; − 2.22] 
and − 4.72  kg [− 5.50; − 3.95], respectively; Fig.  4d). 
The  p-values for all between-group comparisons were 
nonsignificant.
Adverse effects by gender and age
Similar proportions of men and women reported AEs 
across treatment groups (Fig.  5). Proportions of serious 
AEs were comparable between semaglutide and placebo 
for males (32.5 vs 36.2%) and females (27.9 vs 33.0%). The 
most frequently reported AEs were gastrointestinal (GI) 
in nature, and they occurred more often with semaglu-
tide than placebo in both males and females. Female sub-
jects reported more GI AEs in all groups compared with 
men (55.6 vs 48.5% for semaglutide and 37.7 vs 32.0% for 
placebo). Comparable proportions of men and women 
prematurely discontinued treatment due to AEs (12.5 and 
13.9%, respectively). A similar proportion of males and 
females reported hypoglycemia (symptomatic as well as 
severe) with semaglutide as well as placebo treatment.
To investigate the potential effects of age on AEs, a 
series of regression analyses were conducted. One in-
trial AE type was chosen (GI events) and tested both for 
treatment-dependent and treatment-independent linear 
and non-linear effects of age on AE incidence; no clear or 
consistent patterns or significant effects were found (see 
Additional file 1).
Discussion
Treatment guidelines recommend the use of antidiabetes 
agents with proven CV benefits as second-line therapy 
in T2D populations with CVD [2, 4, 18]. All currently 
approved injectable GLP-1RAs have demonstrated CV 
safety (non-inferiority) in CVOTs [12, 19–23], but only 
four have demonstrated both CV safety and superiority 
relative to standard of care [12, 20, 22, 23]. While there 
appears to be a class effect among human-based GLP-1 
analogs with respect to CV benefit, additional studies 
are needed to further elucidate whether CV protective 
effects are provided by all GLP-1RAs [24, 25].
Semaglutide has demonstrated a consistent effect with 
respect to glycemic efficacy and safety in T2D popu-
lations across the spectrum of care [7–14, 26–28]. In 
SUSTAIN 6, subjects with T2D at high CV risk treated 
with semaglutide had a 26% lower risk of the primary 
composite outcome of first MACE (death from CV 
causes, nonfatal MI, or nonfatal stroke) vs those receiv-
ing placebo over 2  years (p = 0.02 for superiority [post 
hoc]) [12]. Results of this post hoc analysis of the SUS-
TAIN 6 trial suggest the beneficial effects of semaglu-
tide vs placebo were similar for men and women, for 
Semaglutide males Placebo males Semaglutide females Placebo females
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48.5
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89.1
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7.1
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Fig. 5 Adverse events by gender in SUSTAIN 6. *On-treatment analysis comprising events with onset from the date of first dose to either the 
end-of-treatment follow-up visit, the date of last dose plus 42 days, the end-of-trial follow-up visit, or the date of withdrawal from trial, whichever 
came first (semaglutide males: n = 1007; semaglutide females: n = 635; placebo males: n = 987; placebo females: n = 657). †Full analysis set 
documented symptomatic hypoglycemia and severe hypoglycemia as defined by the American Diabetes Association [17] (semaglutide males: 
n = 1013; semaglutide females: n = 635; placebo males: n = 989; placebo females: n = 660). AE adverse event
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both younger (50–65 years) and older (> 65) populations 
studied, and for subjects with varying CV risk profiles 
at baseline. Similar results were observed with another 
once-weekly GLP-1RA (exenatide), in which subgroup 
analyses showed a consistent reduction in MACE across 
a range of baseline characteristics, including gender, age, 
and previous CV events [29]. Gender is an important 
determinant of CV risk within T2D [30]. Historically, 
women have reached target values for modifiable CV 
risk factors, including  HbA1c, systolic and diastolic blood 
pressure, and lipid levels, less frequently than men [31–
33]. In the present post hoc analysis, the decreased risk 
of first occurrence of MACE associated with semaglu-
tide treatment vs placebo demonstrated in SUSTAIN 6 
[12] was comparable for both genders, and overall event 
rates were similar or lower for women than men. Given 
the scarcity of available evidence for the effects of T2D 
treatment on CV outcomes in women and the increased 
emphasis on CV risk reduction [2], additional analysis of 
CV outcome trials in T2D by gender could help individu-
alize optimal care and risk management for all patients 
with a history of or risk factors for CVD.
Cardiovascular risk reduction in populations > 65 years 
deserves considerable attention alongside the efficacy 
and safety associated with any intervention. However, 
trials specifically examining the effect of antihypergly-
cemic treatment on CV events in older populations are 
lacking. In this analysis, treatment with semaglutide 
reduced the risk of a MACE and its components in sub-
jects aged 50‒65 and > 65 years. Further subgroup analy-
sis in subjects > 75 years could not be conducted due to 
insufficient numbers for accurate assessment. A post 
hoc analysis from the LEADER (Liraglutide Effect and 
Action in Diabetes: Evaluation of Cardiovascular Out-
come Results) trial examined the effects of liraglutide vs 
placebo in subjects aged ≥ 75 years (n = 836) and in those 
aged 60–74  years (n = 6183) [34]. Treatment with lira-
glutide led to a greater MACE risk reduction in subjects 
aged ≥ 75 years (HR: 0.66 [95% CI 0.49; 0.89]) compared 
with those aged 60‒74  years (HR: 0.95; [95% CI 0.83; 
1.09]) (p = 0.05 for interaction).
A pre-existent history of MI or stroke is an impor-
tant CV risk determinant in subjects with T2D [35, 36]. 
Therefore, the present post hoc analysis divided subjects 
based on clinically relevant factors (prior MI or stroke vs 
no prior MI or stroke and established CVD vs risk factors 
alone) to allow for exploration of CV outcomes across 
these CV risk subgroups. Semaglutide demonstrated 
a consistent reduction in MACE and its components 
vs placebo, regardless of baseline CV risk profile. These 
results may be compared with those of a post hoc anal-
ysis of the LEADER trial, which demonstrated similar 
incidence rates of MACE in the liraglutide vs placebo 
group in subjects with a relatively low baseline CV risk 
(defined as isolated CKD, hypertension with left ventric-
ular hypertrophy, New York Heart Association Class II or 
III heart failure, and left ventricular systolic or diastolic 
dysfunction) [37]. Given the low number of subjects and 
CV events for subjects without established CVD in both 
analyses, however, these results should be interpreted 
with caution. The REWIND (Researching Cardiovascular 
Events with a Weekly Incretin in Diabetes) trial assessed 
the effect of dulaglutide, a GLP-1RA, vs placebo added to 
standard of care in 9901 subjects with T2D. In this trial, 
the majority of subjects did not have established CVD at 
baseline, and the highly anticipated results from the trial 
will add to the body of evidence on the potential role for 
GLP-1RAs on CV risk reduction in a broad range of indi-
viduals with T2D [38].
The current analysis evaluated the tolerability of sema-
glutide across genders and both age groups (50‒65 and 
> 65  years). Overall, a higher proportion of women 
reported GI AEs compared with men, although the rate 
difference between semaglutide and placebo groups was 
similar for both. Of note, the rate of premature treatment 
discontinuation due to AEs was comparable between 
genders, suggesting that the higher reported occurrence 
of GI AEs in women did not result in increased drug dis-
continuation. While it is necessary to examine the safety 
of semaglutide in older populations with T2D, especially 
in those at risk for retinopathy or kidney complications, 
these points are not discussed in this analysis and will be 
explored in future trials [39, 40].
Limitations of the current analysis include the relatively 
short duration of follow-up (2.1 years) and the relatively 
small number of MACE, both in the semaglutide group 
(108/1648 subjects; 6.6%) and in subjects randomized 
to receive placebo (146/1649 subjects; 8.9%), leading to 
weaker statistical power in the subgroup results. In addi-
tion, the older age group in SUSTAIN 6 included  both 
those with established CVD and those with CV risk fac-
tors alone, while the younger group of subjects included 
only those with established CVD. These differences limit 
the ability to make assumptions about the consistency 
of clinical benefit in older T2D populations at high CV 
risk. However, when CV risk composition of all subjects 
in these groups  was explored in this subgroup analy-
sis, the results suggested a similarity irrespective of age. 
Finally, considering the nature of subgroup analyses and 
the risk of false positive effects with a large number of 
comparisons [41], any conclusions should be interpreted 
cautiously and in the context of all available data in the 
literature.
Page 11 of 12Leiter et al. Cardiovasc Diabetol           (2019) 18:73 
Conclusion
In this post hoc analysis of the SUSTAIN 6 trial, once-
weekly semaglutide vs placebo reduced the risk of MACE 
in all subjects regardless of gender, age (50‒65 and 
> 65 years), or baseline CV risk profile (prior MI or stroke 
vs no prior MI or stroke or established CVD vs CV risk 
factors alone). In addition, similar reductions in  HbA1c 
and weight were observed with semaglutide compared 
with placebo across gender and age groups, and safety 
profiles were comparable between men and women and 
in subjects above or below the age of 65 years.
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